Skip to main
GLSI
GLSI logo

Greenwich Lifesciences (GLSI) Stock Forecast & Price Target

Greenwich Lifesciences (GLSI) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Greenwich LifeSciences Inc. is advancing its clinical efforts with the GP2 immunotherapy, demonstrating a 100% reduction in recurrence rates among a specific sub-population in the Phase 2 trial, indicative of strong efficacy in preventing breast cancer recurrences. The company is expanding its trial footprint with the European Medicines Agency (EMA) approving the addition of 11 sites across several countries, facilitating increased enrollment and data collection for improved trial results. Despite a net loss of $2.6 million, the consistent alignment with financial estimates and strategic steps toward broader clinical trials provide a solid foundation for a favorable outlook on the company's future growth and financial performance.

Bears say

Greenwich LifeSciences reported a net loss of $2.6 million in the second quarter of 2024, reflecting ongoing financial challenges as the company continues to develop its GP2 immunotherapy. The potential risks associated with GP2 include the possibility of failure in clinical trials, difficulties in securing regulatory approval, and challenges in gaining commercial traction due to market competition and size. Additionally, concerns regarding dilution further exacerbate the negative outlook, indicating potential hurdles to achieving sustainable profitability despite the company’s current clinical advancements.

Greenwich Lifesciences (GLSI) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Greenwich Lifesciences (GLSI) Forecast

Analysts have given Greenwich Lifesciences (GLSI) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Greenwich Lifesciences (GLSI) has a Strong Buy consensus rating as of Jun 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Greenwich Lifesciences (GLSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.